Rafael Zaragoza Urdaz
Allergy · San Juan, PRNPI 1023166055
Payments from drug & device makers
Across 731 payments — averaging $671.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pharming Healthcare, Inc.$99K
- Regeneron$98K
- Shire North American Group Inc$89K
- Takeda Pharmaceuticals U.S.A., Inc.$87K
- Biocryst US Sales Co., LLC$67K
- AstraZeneca$15K
- plus $37K from 24 others
Across 43 payments — averaging $676.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$29K
What the payments were for
- Consulting fees$47,58317%
- Speaking & faculty fees$200,10972%
- Travel & lodging$13,2325%
- Food & beverage$16,6996%
- Education$640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pharming Healthcare, Inc. | 88 | $98,750 |
| Regeneron | 78 | $97,784 |
| Shire North American Group Inc | 42 | $88,585 |
| Takeda Pharmaceuticals U.S.A., Inc. | 178 | $86,565 |
| Biocryst US Sales Co., LLC | 148 | $67,227 |
| AstraZeneca | 21 | $15,231 |
| Sanofi | 42 | $13,958 |
| Teva Pharmaceuticals USA, Inc. | 9 | $8,890 |
| Regeneron Healthcare Solutions, Inc. | 11 | $4,340 |
| Biocryst Pharmaceuticals, Inc. | 6 | $3,691 |
| AbbVie | 9 | $2,230 |
| PBG Puerto Rico LLC | 31 | $503 |
| GSK | 9 | $351 |
| Pfizer | 5 | $332 |
| Mylan Specialty L.p. | 7 | $289 |
| Amgen(2 entities) | 7 | $283 |
| Genentech USA, Inc. | 9 | $262 |
| Blueprint Medicines Corporation | 2 | $257 |
| Novartis | 8 | $231 |
| Genentech, Inc. | 3 | $163 |
| Boehringer Ingelheim | 2 | $136 |
| Jazz Pharmaceuticals Inc. | 1 | $133 |
| Lilly USA, LLC | 1 | $119 |
| Alk-abello, Inc | 1 | $117 |
| Sanofi-aventis U.S. LLC | 2 | $86 |
| CSL Behring | 2 | $58 |
| Mylan LLC | 6 | $57 |
| Mallinckrodt Hospital Products Inc. | 1 | $34 |
| Sanofi US Services Inc. | 1 | $19 |
| Pfizer Pharmaceuticals LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RUCONEST$97,699
- Orladeyo$68,256
- CINRYZE$49,114
- TAKHZYRO$18,955
- DUPIXENT$17,117
- ProAir Digihaler$8,700
- ArmonAir Digihaler$8,700
- AirDuo RespiClick$8,700
- TEZSPIRE$2,694
- Rinvoq$620
- AYVAKIT$257
- Yupelri$230
- XYWAV$133
- GLASSIA$123
- CUVITRU$122
- DERMATITIS - DISEASE$120
- ASTHMA - DISEASE$120
- NASAL POLYPOSIS - DISEASE$120
- TRELEGY ELLIPTA$117
- Odactra$117
How this compares
Too few allergy providers in Puerto Ricoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 74 | $2,956,657 |
| FirazyrIcatibant Acetate | 29 | $965,052 |
| Dupixent SyringeDupilumab | 46 | $174,911 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $21,907 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 120 | $11,805 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,620 |
| Epinephrine | 17 | $4,135 |
| Methylprednisolone | 194 | $3,778 |
| Clobetasol Propionate | 46 | $3,474 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 19 | $3,136 |
| Levocetirizine Dihydrochloride | 236 | $2,694 |
| Desloratadine | 66 | $1,560 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 25 | $1,498 |
| Fluocinolone Acetonide Oil | 20 | $1,479 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $1,371 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro, Firazyr | $86,565 | $3,921,709103 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $351 | $26,52744 claims |
| AbbVieSynthroid | $2,230 | $67912 claims |
| Teva Pharmaceuticals USA, Inc.Albuterol Sulfate | $8,890 | $46564 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Puerto Ricoon file to place this against a meaningful peer group, so we don't.
Other allergy in San Juan
- Vylma Velazquez AlmodovarPonce$3K
- Maristely Rodriguez RoaVega Alta$2K
- Luis Torres VeraHato Rey$319
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.